Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Merck
MRK
Merck
Merck & Co.: Navigating Pharmaceutical Frontiers Amidst Patent Challenges
BU
bucailei
Not Invested
Community Contributor
Published
28 Sep 24
Updated
02 Oct 24
7
Set Fair Value
1
votes
Share
bucailei
's Fair Value
US$112.55
28.3% undervalued
intrinsic discount
02 Oct
US$80.69
Loading
1Y
-28.9%
7D
1.0%
Author's Valuation
US$112.6
28.3% undervalued
intrinsic discount
bucailei's Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
bucailei
's
Fair Value
US$112.6
28.3% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
73b
2013
2016
2019
2022
2024
2025
2027
Revenue US$72.9b
Earnings US$16.0b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
2.97%
Pharma revenue growth rate
1.01%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$16.02b
Earnings '27
x
20.98x
PE Ratio '27
=
US$336.03b
Market Cap '27
US$336.03b
Market Cap '27
/
2.53b
No. shares '27
=
US$132.99
Share Price '27
US$132.99
Share Price '27
Discounted to 2024 @ 5.80% p.a.
=
US$112.31
Fair Value '24
